Malignant pleural mesothelioma (MPM) is a rare pleural cancer, which could be primary or secondary to an asbestos exposure. To enhance our knowledge of this rare disease, an exploration of genetic and tumor mechanism is mandatory. One of the principal difficulty is to harvest sufficient tumour pieces to perform multi-omics analysis. The goal of the SCITH-MESO study is to harvest larges pieces of tumour during a routine surgical procedure of MPM diagnosis by mean of pleural biopsies during VATS surgery. Operating samples will increase a tissue bank collection (CRB).
Surgery can be hard on the body, but it can help some mesothelioma patients if done a second time. People could still have a good quality of life and even an extended survival if they undergo the aggressive surgery. This surgery is not common and would not be recommended for[…]
Dielectric Properties of Matched Tissue Samples From Thoracic Malignancies and Corresponding Normal Tissues
The purpose of the Dielectrics Properties of Thoracic Malignancies Study (DPTMS) is to provide a wealth of knowledge for investigators involved in establishing a new and effective treatment for a variety of solid tumors using tumor treatment fields. It is intended to provide biospecimen (tumor/healthy) together with demographic data (age, sex, race, occupational history, and other epidemiologic information), and clinical data (stage, treatment, survival information, and annotated CT’s). Our specific aims are to test the following hypotheses: 1) Electric properties of thoracic tumors differ from electric properties of surrounding healthy tissue 2) Different tumor types will have different electric properties 3) Electric properties of individual tumors are heterogeneous 4) Electric properties of tumors are related to the structure and composition of the underlying tissue 5) Use of standard medical imaging data (CT) will permit mapping of electric properties.
Mesothelioma is not found in as many women as men, but studies show that women can survive longer than men. Researchers at the International Mesothelioma Program at Brigham and Women’s Hospital in Boston found that a gene can help predict the prognosis and treatment outcome for women patients with mesothelioma.[…]
Primary Outcome Measures Prevalence of germline BAP1 variants in the unselected general population of cancer patients [ Time Frame: 5 years ] Clinical phenotypes (this includes premalignant lesions, tumor type and age of onset) in at risk blood-line family members of the patients [ Time Frame: 5 years ] Secondary Outcome Measures Environmental risk factors modifying cancer risk[…]
There is promising new data from the makers of ONCOS-102 that shows that the treatment can help improve the long-term survival of mesothelioma patients. ONCOS-102 was recently given Fast-Track approval by the FDA to speed up its development. ONCOS-102 is a modified adenovirus that infects cancer cells. The new mesothelioma[…]
Evaluation of the Clinical/Biological Characteristics, Efficacy and Safety of Patients With Malignant Pleural Mesothelioma, Treated by Immunotherapy (MESOIMMUNE)
Primary Outcome Measures Disease control [ Time Frame: 12 weeks ] Disease control rate at 12 weeks Secondary Outcome Measures Survival with anti-PD1/PDL1 immunotherapy [ Time Frame: 12 weeks ] Overall survival from treatment with anti-PD1/PDL1 immunotherapy Duration of treatment [ Time Frame: 12 weeks ] Duration of treatment with PD1/PDL1 immunotherapy Survival [ Time Frame: 12 weeks ] Overall survival from the start of the[…]
Researchers are Developing a Test to Determine Which Mesothelioma Patients Will Benefit From Immunotherapy
Doctors want to figure out which pleural mesothelioma patients will best benefit from certain chemotherapy drugs. Currently there are no tests to see what immunotherapy drugs might work on a specific patient. This leads to doctors trying out different treatments that have negative side effects to only find out the[…]
Genetic Testing Could Help Reduce Mesothelioma Cases and Help the Survival of Those Suffering from the Disease
Researchers believe that early genetic testing for genetic mutations can help reduce the cases of mesothelioma and can help increase the survival of those suffering from the disease. Researchers found that new mutations in the BLM gene were making people more susceptible to developing mesothelioma after being exposed to asbestos.[…]
A study in the United Kingdom involving 332 patients who cannot receive surgery (unresectable) found that patients whose mesothelioma has relapsed can be treated with nivolumab safely. Nivolumab is an immunotherapy drug known as Opdivo, which is popular for treating non-small cell lung cancer. Opdivo is promising because it is[…]